All In Biotech

NDA 021015 · Besins Hlthcare

Androgel

Testosterone · Transdermal · Androgen

Last checked: Nov 19, 2026Latest source record: Jul 11, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2000

Feb 28, 2000

Approved uses

2

Original approval plus efficacy supplements

Registered trials

728

173 Phase 3, 64 recruiting

FAERS reports

19,071

10,928 serious, 779 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SECONDARY EXPOSURE TO TESTOSTERONE Virilization has been reported in children who were secondarily exposed to testosterone gel [see Warnings and Precautions ( 5.2 ) and Adverse Reactions ( 6.2 )] . Children should avoid contact with unwashed or unclothed application sites in men using testosterone gel [see Dosage and Administration ( 2.2 ) and Warnings and Precautions ( 5.2 )] . Healthcare providers should advise patients to strictly adhere to recommended instructions for use [see Dosage and Administration ( 2.2 ), Warnings and Precautions ( 5.2 ) and Patient Counseling Information ( 17 )] . WARNING: SECONDARY EXPOSURE TO TESTOSTERONE See full prescribing information for complete boxed warning. Virilization has been reported in children who were secondarily exposed to testosterone gel. ( 5.2 , 6.2 ) Children should avoid contact with unwashed or unclothed application sites in...

What it is approved for

From the label in effect Dec 1, 2024.

Testosterone gel 1% is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired): testicular failure due to conditions such as cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range. Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum concentrations, but have gonadotropins in the normal or low range. Limitations of use: Safety and efficacy of testosterone gel 1% in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established. Safety and efficacy of testosterone gel 1% in males less than 18 years old have not been established [see Use in Specific Populations ( 8.4 )] . Topical testosterone products may have different doses, strengths or application instructions that may result in different systemic exposure ( 1 , 12.3 ). Testosterone gel 1% is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired). ( 1 ) Hypogonadotropic hypogonadism (congenital or acquired). ( 1 ) Limitations of use: Safety and efficacy of testosterone gel 1% in men with “age-related hypogonadism” have not been established. ( 1 ) Safety and efficacy of testosterone gel...

Mechanism: Endogenous androgens, including testosterone and dihydrotestosterone (DHT), are responsible for the normal growth and development of the male sex organs and for maintenance of secondary sex characteristics. These effects include the growth and maturation of prostate, seminal vesicles, penis and scrotum; the development of male hair distribution, such as facial, pubic, chest and axillary hair; laryngeal enlargement, vocal chord thickening, alterations in body musculature and fat distribution. Testosterone and DHT are necessary for the normal development of secondary sex characteristics. Male...

Therapeutic areas: Endocrinology and women's health

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • ANDROGEL · TESTOSTERONE 50MG/5GM PACKET · GEL, TRANSDERMAL · Prescription · TE AB1
  • ANDROGEL · TESTOSTERONE 12.5MG/1.25GM ACTUATION · GEL, METERED, TRANSDERMAL · Prescription · TE AB1
  • ANDROGEL · TESTOSTERONE 25MG/2.5GM PACKET · GEL, TRANSDERMAL · Prescription · TE AB1

Clinical trials

Interventional ClinicalTrials.gov studies with "Testosterone" as an intervention, any sponsor and status, largest first.

All 728 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective1,467
  • off label use1,232
  • fatigue1,182
  • nausea858
  • headache776
  • pain776
  • diarrhoea628
  • anxiety611
  • asthenia598
  • arthralgia595
  • dizziness593
  • dyspnoea549

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004169
2005126
2006139
2007156
2008188
2009248
2010307
2011334
2012875
2013367
2014556
20151,102
20161,059
2017977
20181,138
20191,225
20201,198
20211,206
20221,419
20231,550
20241,640
20251,721
20261,371

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Androgel (Testosterone)

2024 spending

$3.9M

Beneficiaries

819

3,365 claims

Per beneficiary

$4,719

$7.63 per unit

View as table
YearSpending
2020$16,306,004
2021$11,136,663
2022$7,361,394
2023$5,098,373
2024$3,864,699

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 6,507 on PubMed

Sponsor: Besins Hlthcare

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.